Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
J&J's immune disorder drug succeeds in studies
08:33am, Monday, 05'th Feb 2024
Johnson & Johnson's experimental drug to treat two autoimmune disorders met the main goals in mid-stage and late-stage trials, the company said on Monday.
February Dogs Of The Dow: Buy 2, Watch 5
11:54am, Sunday, 04'th Feb 2024
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�
2 Healthcare Dividend Kings to Buy and Hold Forever
08:20am, Sunday, 04'th Feb 2024
Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovation
5 Relatively Secure And Cheap Dividend Stocks To Invest In - February 2024
09:00am, Saturday, 03'rd Feb 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Dow Stocks To Trade In February
09:39am, Thursday, 01'st Feb 2024
For this month, the cycle/relative strength concept is applied. First, the Dow Jones 30 stocks are ranked from the best performer to the worst by calculating the expected return in that month.
The 7 Best Blue-Chip Stocks to Invest In for Big Gains in 2024
11:56am, Wednesday, 31'st Jan 2024
While technology stocks continue to drive the market higher, they are not the only game in town. Investors needn't invest only in semiconductor stocks to achieve big gains.
4 med tech stocks with improving prognosis for 2024
07:20am, Wednesday, 31'st Jan 2024
Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate,
Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
02:14pm, Tuesday, 30'th Jan 2024
As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies.
Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat
01:52pm, Tuesday, 30'th Jan 2024
J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.
3 Blue Chip Stocks To Watch Ahead Of February 2024
10:54am, Tuesday, 30'th Jan 2024
Blue chip stocks to watch in the stock market before February 2024.
3 Perfect Stocks for Retirees to Buy Hand Over Fist in the New Bull Market
05:06am, Tuesday, 30'th Jan 2024
The benchmark S&P 500 recently climbed to a new all-time high, signaling without a shadow of a doubt that we're in a bull market. Bargains can still be found, even with the broader market hitting fres
Pharma industry to get US government price cut proposals by Thursday
11:35am, Monday, 29'th Jan 2024
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 29'th Jan 2024
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
08:00am, Sunday, 28'th Jan 2024
Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.
Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments
01:26am, Sunday, 28'th Jan 2024
Johnson & Johnson is a multinational corporation in the healthcare and pharmaceutical sectors, showing indications of accelerated growth. J&J is currently the third largest player in the pharmaceutica
